SmithKline Beecham Pharmaceuticals - UK
| Държава: | Германия |
| Кратка информация: | 2000 GlaxoSmithKline is formed through the merger of Glaxo Wellcome and SmithKline Beecham. Avandia passes one million retail prescriptions in the US. GSK makes a ground-breaking pledge to provide three HIV/AIDS medicines to developing country governments at significant price reductions. 2001 GSK moves to its new UK headquarters in Brentford, West London. GSK House consists of four, five-storey buildings and a 16-storey tower block linked by an internal fully-glazed 'street'. The building was designed with input from employees. Twinrix, the first combination vaccine to prevent hepatitis A and B is approved by the FDA. GSK reorganises its research and development efforts into Centres of Excellence for Drug Development (CEDDs), small business units that emphasise flexibility, innovation and therapeutic focus. GSK launches Advair, an anti-asthma medicine, in the US and acquires the Sensodyne range of oral care products. GSK launches the African Malaria Partnership to help combat a disease that kills more than one million people every year. 2002 Avandia reaches 20 million prescriptions milestone in the US. GSK donated the first 100 million albendazole tablets as part of its commitment to fight lymphatic filariasis. GSK marks the 15th anniversary of AZT, the first medicine used to treat HIV/AIDS. GSK‘s Positive Action programme celebrates its tenth anniversary. By the end of 2002, GSK had secured 120 arrangements to supply preferentially-priced HIV/AIDS medicines to 50 of the world‘s poorest countries. 2003 On 27 July 2003, ten million people in Sri Lanka received free doses of GSK-donated albendazole to help prevent the transmission of lymphatic filariasis. GSK launches Wellbutrin XL, an anti-depressant medicine, in the US. 2004 GSK ships 33 million tablets of preferentially-priced Combivir (HIV treatment) to Africa. GSK launches its Clinical Trial Register, an Internet site containing clinical trial data that anyone can access. GSK is the first pharmaceutical company to offer this level of transparency for its clinical trial data. 2005 GSK launches Rotarix, a vaccine against rotavirus, a major cause of vomiting and diarrhoea in infants. The launch programme of the product focuses on markets where the need is highest. GSK donates medicines and vaccines in response to the Asian Tsunami disaster of December 2004 and devastation caused by Hurricane Katrina in the USA in August 2005. GSK announces the FDA approval of Fluarix, an influenza virus vaccine. GSK CEO JP Garnier meets US President Bush to discuss pandemic flu planning. GSK is highlighted by Bill Gates of the Bill & Melinda Gates Foundation in recognition of the company's commitment to R&D on malaria and other neglected diseases. GSK take steps to bolster it leadership position in pandemic flu preparedness by investing in flu vaccine production facilities, the acquisition of vaccines production facilities and the development of candidate pandemic flu vaccines. 2006 GSK produces over 10 million packs of its anti-flu treatment Relenza in one year. To boost its consumer healthcare portfolio, GSK acquires CNS Inc., producers of the Breathe Right nasal dilator strips and FiberChoice dietary fibre supplements. By the end of 2006, 600 million treatments for lymphatic filariasis had been donated as part of the company's commitment to eradicate this disease. GSK wins New Business Award for efforts to end lymphatic filariasis. Rotarix, the first vaccine against rotavirus is made available in Europe. 2007 In a busy year for acquisitions, GSK acquires Domantis, a leader in developing antibody therapies, Praesis Pharmaceuticals, a biopharmaceuticals company and Reliant Pharmaceuticals, a producer of cardiovascular medicines. GSK launches alli, over-the-counter orlistat, for first FDA-approved treatment for obesity in the US. GSK gains US approval for Tykerb, a new treatment for advanced breast cancer. Cervarix, GSK‘s cervical cancer vaccine approved in Europe. GSK announces submission of combination vaccine Globorix to the European Medicines Agency (EMEA) with the intention of providing the vaccine to Africa with no commercial reward. Andrew Witty named CEO Designate to replace JP Garnier in May 2008 GSK obtains exclusive US OTC marketing rights to Mevacor (lovastatin) from Merck & Co., Inc. New R&D centre opened in China. 2008 GSK marks the ten year anniversary of its commitment to eliminate lymphatic filariasis. New allergic rhinitis treatment Avamys approved in Europe. GSK reduces prices for anti-retrovirals in the world's poorest countries. FDA approves Rotarix, a vaccination against rotavirus. FDA approves Treximet for the treatment of migraine. Andrew Witty succeeds JP Garnier as Chief Executive Officer. GSK acquires Sirtris Pharmaceuticals Inc, a world leader in sirtuin research and development. FDA approves Requip XL, an oral treatment for Parkinson‘s disease. Cervarix, GSK's cervical cancer vaccine, wins tenden for UK national immunisation programme. GSK sets out three new strategic priorities: grow a diversified global business; deliver more products of value; simplify the operating model. GSK acquires the leading dry mouth brand, Biotene. GSK ceases providing corporate political contributions. 2009 Weight loss medicine alli launches in Europe. Synflorix, GlaxoSmithKline‘s pneumococcal vaccine, receives European authorisation. GSK‘s commitment to emerging markets is strengthened through agreements with Aspen, Dr. Reddy‘s and UCB. GSK becomes a leader in skincare with the acquisition of Stiefel. As influenza A (H1N1) spreads across the world, GSK commits to tackling the pandemic with its anti-retroviral and vaccine products. GSK and Pfizer launch ViiV Healthcare, a new company focused on delivering advances in treatment and care for HIV communities. Agreement reached to launch Lucozade in China. GSK‘s H1N1 Pandemrix vaccine receives European Commission Approval. Cervarix approved in USA and Japan. World‘s largest malaria vaccine trial gets underway in seven African countries. GSK signs agreement with the World Health Organization to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries. GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed. As part of its commitment to greater transparency, GSK publishes speaking and consulting fees paid to US physicians. 2010 GSK contributes $1.4 million of medicines to support victims of the Haiti earthquake. GSK announces open innovation strategy to help deliver new and better medicines for people living in the world‘s poorest countries. New collaborations will share intellectual property for neglected tropical diseases such as malaria. GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world‘s poorest countries. European approval granted for Duodart. GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix. GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine. GSK and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases. GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China. 2011 GSK announces move to new environmentally-friendly building in Philadelphia USA. Rapid introduction of Synflorix™ in Kenya at around 90% discount enables vaccination of millions of children against pneumococcal disease. Launch of Sensodyne Repair & Protect, the world’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth. GSK to reimburse 100% of uncapped tuition fees for all undergraduates it recruits in the UK. GlaxoSmithKline and Human Genome Sciences receive approval for Benlysta® (belimumab), the first new lupus treatment in 50 years. |
| Сайт: | http://www.gsk.com/about/history-noflash.htm |
